title: Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).
abstract: The authors report the results of 58 children with ALL in 2CR after related (n = 31) or unrelated (n = 27) AHSCT. Characteristics at diagnosis and initial and after relapse antileukemic treatment were similar in the related donor (RD) and the unrelated donor (UD) groups. Conditioning consisted of TBI/CY +/- VP-16 for patients > or = 3 years old (n = 43) and Bu/CY for the rest. Median recipient age was 8 years (range 1-17) in the RD and 9 years (range 3-14) in the UD group. Median follow-up was 54 months (range 24-80) and 52 months (range 22-85) in the RD and the UD groups repectively. The 5-year EFS probability was 43 +/- 9% for the RD group and 36 +/- 9% in the UD group (p = .25). The transplant-related mortality was 16% in the RD and 37% in the UD group (p = .016). In the RD group 36.7% of patients relapsed versus 18.6% in the UD group (p = .05). GvHD associated with organ failure or infection caused most of the transplant-related deaths in both groups. Survivor quality of life for both groups was good (Lansky score < or = 90).
authors.affiliation: Hospital Ramon y Cajal-University of Alcala, Madrid, Spain. amvillatv@yahoo.es
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
authors.forename: C
authors.initials: C
authors.lastname: Diaz-Heredia
authors.forename: M A
authors.initials: MA
authors.lastname: Diaz
authors.forename: I
authors.initials: I
authors.lastname: Badell
authors.forename: A
authors.initials: A
authors.lastname: Verdeguer
authors.forename: A
authors.initials: A
authors.lastname: Martinez
authors.forename: P
authors.initials: P
authors.lastname: Gomez
authors.forename: J M
authors.initials: JM
authors.lastname: Perez-Hurtado
authors.forename: E
authors.initials: E
authors.lastname: Bureo
authors.forename: R
authors.initials: R
authors.lastname: Fernandez-Delgado
authors.forename: M E
authors.initials: ME
authors.lastname: Gonzalez-Valentin
authors.forename: M S
authors.initials: MS
authors.lastname: Maldonado
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome